Testing QLC5508, a new cancer drug, in advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This early-stage trial tests QLC5508, an experimental cancer medication, in patients with advanced solid tumors that haven't responded to standard treatments. The study focuses on safety, how the drug moves through your body, and potential interactions with other medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer (solid tumor) that has failed standard treatment or you cannot tolerate it
- Your overall health status is good enough for treatment (ECOG score of 0 or 1)
- You have normal heart function (ejection fraction ≥50%) and a normal heart rhythm on EKG
- Your blood counts, kidney function, and liver function are adequate
- You have recovered from side effects of previous cancer treatments to mild levels (Grade 1 or less)
- You agree to use reliable birth control for at least 6 months after your last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a new combination of drugs for people with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and improve outcomes.
This trial tests an experimental drug (called QLS5308) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug can shrink tumors or slow their growth, and to find the best dose with manageable side effects.
This trial tests a combination of two new treatments (QLP2117 and QL2107) for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination can shrink tumors or slow cancer growth.
This trial tests a new drug called QLS5133 for people with advanced solid tumors (cancers that have spread). The drug may help shrink tumors or slow their growth. The study is in two phases to find the right dose and see how well it works.
This trial tests a new drug called QLS5212 in people with solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and effective.
Hear when a new Refractory or Relapsed Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.